Revenues are expected to be $2.32 million, up 82.7% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 11.36% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Zacks Consensus Estimate This company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change ...

Company Overview - Absci Corporation is a clinical-stage biopharmaceutical company focused on advancing drug discovery through generative design, aiming to create better biologics for patients more rapidly [3] - The company utilizes its Integrated Drug Creation™ platform, which combines AI models with a synthetic biology data engine, to innovate therapeutics targeting challenging therapeutic areas [3] Upcoming Financial Results - Absci will report its business updates and financial results for the second quarter of 2025 after market close on August 12, 2025 [1] - A conference call will be held at 4:30 p.m. Eastern Time to discuss these results and the company's outlook, with a live webcast available on its investor relations website [2] Product Pipeline - Absci is developing a pipeline of AI-designed therapeutics, including ABS-101, aimed at treating inflammatory bowel disease (IBD), and ABS-201, which targets hair regrowth for androgenetic alopecia [3] - The company collaborates with leading pharmaceutical, biotech, tech, and academic institutions to enhance its therapeutic innovations [3]

Core Insights - Absci has appointed Mary Szela, a veteran biopharmaceutical executive, to its Board of Directors, bringing over three decades of commercial and clinical leadership experience [1][2] - Szela's expertise includes the global launch and expansion of Humira, a highly successful therapy, and she has held significant roles in various biopharmaceutical companies [2][3] - Absci is focused on accelerating the development of its AI-designed therapeutics, including ABS-101 for inflammatory bowel disease and ABS-201 for androgenetic alopecia [3][4] Company Overview - Absci is a clinical-stage biopharmaceutical company utilizing generative AI to create innovative biologics, aiming to enhance drug discovery and development processes [4] - The company's Integrated Drug Creation™ platform combines advanced AI models with synthetic biology, facilitating rapid design and validation of therapeutics [4] - Absci's pipeline includes ABS-101, an anti-TL1A antibody for inflammatory bowel disease, and ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia, with clinical developments expected in the near future [3][4]

Summary of Abzai (ABSI) FY Conference Call Company Overview - Abzai is a generative AI drug creation company focused on solving complex biological problems to deliver differentiated assets to patients faster [1] - The company has a data-first approach and has developed a world-class AI platform leveraging expertise from leading tech companies [2] Core Technology and Pipeline - Abzai's original technology involves scaling protein-protein interactions, allowing the screening of millions of antibodies [2] - The company employs a "lab in the loop" model, enabling rapid iteration on model designs and architectures [6] - Abzai is targeting hard-to-drug targets such as ion channels and GPCRs, with a strong internal pipeline and partnerships with large pharma [3][13] Key Assets - **ABS 101**: An anti-TL1A antibody for inflammatory bowel disease (IBD) that entered the clinic in May 2025. It shows a 3x increase in target engagement compared to first-generation antibodies and is designed for convenient at-home self-injection [4][17][18] - **ABS 201**: An anti-prolactin receptor antibody targeting androgenic alopecia, which affects over 80 million patients in the US. It aims to shift hair follicles back into the active growth phase, showing promising durability and efficacy compared to standard treatments like minoxidil [21][22][32] Clinical Data and Efficacy - ABS 101 is expected to have a phase one interim readout in the second half of 2025, with potential for quarterly dosing due to its extended half-life [18][34] - ABS 201 has demonstrated superior efficacy in preclinical models, with faster hair regrowth compared to minoxidil and high bioavailability [28][29][30] Market Potential - The market for androgenic alopecia treatments is significant, with over 80 million Americans affected. The company sees ABS 201 as a first-in-class asset with untapped market potential [31][32] - The company anticipates a large pharma partnership by the end of 2025, which could provide significant upfront capital [34] Strategic Partnerships - Abzai has established partnerships with large pharma and biotech firms to leverage their domain expertise and enhance its AI capabilities [13][14] - Collaborations with organizations like Caltech and the Gates Foundation have led to breakthroughs in drug design, particularly for hard-to-drug targets like HIV [9][10] Conclusion - Abzai is positioned to leverage generative design to create differentiated biologics, with a strong pipeline and strategic partnerships aimed at accelerating drug development and improving patient outcomes [35]

Summary of AbSci (ABSI) Conference Call Company Overview - AbSci is a generative AI drug creation company focused on tackling complex biological problems using advanced AI models and a unique integrated data flywheel [2][3] Key Points Industry and Market Position - AbSci operates in the biotechnology sector, specifically in drug development using AI technology [2] - The company has established a world-class pipeline targeting indications in immunology and oncology [4] Pipeline and Assets - Lead asset ABS 101 is focused on inflammatory bowel disease (IBD) and has recently initiated a Phase 1 trial, with interim readout expected in the second half of the year [4][18] - ABS 201 targets androgenic alopecia (common baldness) and is anticipated to enter the clinic early next year [4][19] - Early-stage pipeline includes ABS 301 and ABS 501, both oncology assets [5] Technological Advancements - AbSci utilizes a "wet lab in the loop" approach, allowing rapid iteration from data collection to model training and validation within six weeks [3][6] - The company has developed proprietary AI models for de novo antibody design and lead optimization, enabling the creation of novel therapeutics [8][32] Case Studies and Collaborations - Successful partnership with the Gates Foundation and Caltech led to the design of an antibody targeting the caldera region of the HIV virus, a previously undruggable target [9][11] - Collaborations with large pharmaceutical companies like Almirall and Merck to co-develop drugs for difficult targets [12][39] Market Opportunity - The hair regrowth market, particularly for ABS 201, is estimated to be over $14 billion annually, with significant unmet medical needs [28] - The company believes that ABS 201 could provide superior efficacy and durability compared to existing treatments like minoxidil and finasteride [19][25] Clinical Development and Future Plans - ABS 101's Phase 1 trial is set to provide interim results by the end of Q3 or beginning of Q4 [18][29] - Plans to pursue ABS 201 through to approval, indicating confidence in its market potential [40] Financial and Strategic Outlook - Anticipation of a new large pharma partnership that could provide significant upfront capital, extending the company's runway [29] - The company is positioned for a catalyst-rich year ahead, driven by its generative AI design platform [29] Additional Insights - The company emphasizes the importance of interdisciplinary collaboration, combining expertise in AI and clinical trial design to enhance drug development [13][14] - AbSci's approach to drug development is characterized by a focus on hard-to-drug targets, leveraging advanced screening technologies [36] This summary encapsulates the key points discussed during the conference call, highlighting AbSci's innovative approach, pipeline assets, market opportunities, and strategic direction.

Absci Corporation (ABSI) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 8.70%. A quarter ago, it was expected that this company would post a loss of $0.22 per share when it actually produced a loss of $0.25, delivering a surprise of -13.64%. Over the last four quarters, the company has surp ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $1.2 million, reflecting ongoing progress in partner programs [20] - Research and development expenses increased to $16.4 million from $12.2 million in the prior year, driven by advancements in internal programs and increased personnel costs [21] - Selling, general and administrative expenses rose to $9.5 million from $8.7 million in the prior year, primarily due to higher stock compensation expenses [21] - The company ended the quarter with $134 million in cash and short-term investments, up from $112.4 million at the end of 2024 [21][22] Business Line Data and Key Metrics Changes - The company initiated its first in-human clinical trial for ABS 101, marking its transition to a clinical stage biotech [7][19] - ABS 101 is a potential best-in-class anti-CL1A antibody, with a focus on safety, tolerability, pharmacokinetics, and pharmacodynamics in a trial involving approximately 40 healthy adult volunteers [8][9] - ABS 201, targeting androgenetic alopecia, is progressing towards a first-in-human trial expected in early 2026, with promising preclinical data supporting its efficacy [11][13] Market Data and Key Metrics Changes - The market for androgenetic alopecia treatments is significant, affecting approximately 80 million adults in the U.S. alone, with ABS 201 representing a potential new category of therapy [11] - The company is exploring additional indications for ABS 201 beyond androgenetic alopecia, including endometriosis [37] Company Strategy and Development Direction - The company aims to leverage its AI platform to design novel therapeutics that address unmet medical needs, focusing on high-value proprietary internal programs [18][22] - The strategy includes retaining and developing ABS 201 through later stages of clinical development to maximize value [20] - The company is also pursuing partnerships with large pharma companies to enhance its drug creation capabilities [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute across its portfolio, with a strong balance sheet supporting ongoing investments in internal programs [22][24] - The FDA's recent proposals to reduce animal testing align with the company's AI-driven approach to drug development, positioning it favorably in the evolving regulatory landscape [15][16][70] Other Important Information - The company is advancing a bispecific program alongside ABS 101, with details to be shared later for competitive reasons [10] - The company is committed to innovation and improving patient outcomes through its AI-driven drug discovery platform [17][25] Q&A Session Summary Question: What are the expectations for ABS 101's phase one trial results? - Management is looking for a favorable safety profile and target engagement data similar to previous presentations [28][29] Question: Can ABS 201 be self-administered in the future? - Management believes it could be self-administered but will initially work with dermatologists for effective administration [31] Question: How is the market segmentation for ABS 201 being approached? - The company sees potential efficacy across various segments of the androgenetic alopecia population and will evaluate this in clinical trials [35][36] Question: What is the expected dosing strategy for ABS 201 based on NHP data? - The anticipated dosing is every eight to twelve weeks, with a treatment period of six months [41] Question: What is the strategy behind pursuing a novel target for the bispecific antibody? - The company aims to explore a difficult-to-drug target that could provide strong synergy with its existing assets [76][77]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $1.2 million, reflecting ongoing progress in partner programs [19] - Research and development expenses increased to $16.4 million from $12.2 million in the prior year, driven by advancements in internal programs [19] - Selling, general and administrative expenses rose to $9.5 million from $8.7 million, primarily due to increased stock compensation [20] - Cash, cash equivalents, and short-term investments at the end of the quarter totaled $134 million, up from $112.4 million as of December 31, 2024 [20] Business Line Data and Key Metrics Changes - The company initiated its first in-human clinical trial for ABS 101, marking its transition to a clinical-stage biotech [6] - ABS 201, targeting androgenetic alopecia, is progressing towards a first-in-human trial expected in early 2026 [13] - The company is advancing multiple programs, including ABS 301 and ABS 501, with ongoing preclinical studies [14][42] Market Data and Key Metrics Changes - ABS 201 targets a market of approximately 80 million adults in the U.S. affected by androgenetic alopecia, with potential for significant therapeutic innovation [11] - The company is exploring additional indications for ABS 201, including endometriosis, indicating a broader market strategy [34] Company Strategy and Development Direction - The company aims to leverage its AI platform to design novel therapeutics addressing unmet medical needs, focusing on high-value proprietary internal programs [17] - Plans to retain and develop ABS 201 through later stages of clinical development to maximize value [19] - The company is engaged in discussions with potential partners for drug creation partnerships, anticipating signing agreements with large pharma [16][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute across its portfolio, with a strong balance sheet supporting ongoing investments [21] - The FDA's proposal to reduce animal testing aligns with the company's AI-driven approach to drug development, presenting a favorable regulatory environment [15][67] - Management expects to see enhanced deal terms for future partnerships due to recent clinical successes [61] Other Important Information - The company is committed to leading biotech innovation through AI, aiming to deliver life-changing treatments [16] - Interim results from the ABS 101 trial are expected later in 2025, with a focus on safety and tolerability [8][24] Q&A Session Summary Question: What are the expectations for ABS 101's phase one top line results? - Management is looking for a favorable safety profile, low immunogenicity, and target engagement similar to previous data presented [26][27] Question: Can ABS 201 potentially be self-administered in the future? - Management believes it could be self-administered but will initially work with dermatologists for effective administration [28] Question: How is market segmentation being approached for ABS 201? - The company sees potential efficacy across various segments of the androgenetic alopecia population and will evaluate this in clinical trials [31][33] Question: What is the expected timeline for ABS 301's development candidate? - The company is progressing towards a drug candidate nomination but has not disclosed a specific timeline [42] Question: How does the company view its cost structure in the current market? - The company is focused on leveraging efficiencies from its AI platform to potentially reduce costs and reallocate resources [62]

Financial Performance - Partner program revenue increased to $1,179,000 for the three months ended March 31, 2025, compared to $898,000 in the same period of 2024, representing a growth of approximately 31.2%[21] - The net loss for the three months ended March 31, 2025, was $26,346,000, compared to a net loss of $21,975,000 for the same period in 2024, indicating a year-over-year increase in losses of approximately 19.5%[21] - For the three months ended March 31, 2025, the net loss was $26.346 million, compared to a net loss of $21.975 million for the same period in 2024, representing an increase of approximately 19% in net loss year-over-year[25] - The company reported an operating loss of $27,729,000 for Q1 2025, compared to an operating loss of $23,498,000 in Q1 2024, reflecting a deterioration of about 17.5%[21] - Total operating expenses rose to $28,908,000 in Q1 2025, up from $24,396,000 in Q1 2024, reflecting an increase of about 18.5%[21] - Total stock-based compensation expense for the three months ended March 31, 2025, was $4.943 million, compared to $3.597 million for the same period in 2024, reflecting a 37.5% increase[48] Cash and Assets - Cash and cash equivalents increased to $46,995,000 as of March 31, 2025, from $41,213,000 as of December 31, 2024, showing a growth of about 14.0%[20] - Total assets grew to $232,447,000 as of March 31, 2025, compared to $213,608,000 as of December 31, 2024, marking an increase of approximately 8.8%[20] - As of March 31, 2025, the company had cash, cash equivalents, and restricted cash totaling $64.125 million, down from $76.307 million at the end of the first quarter of 2024, a decrease of about 16%[25] - The company’s investments in short-term investments as of March 31, 2025, were valued at $86.988 million, compared to $71.212 million as of December 31, 2024, representing an increase of approximately 22%[35] - The total stockholders' equity as of March 31, 2025, was $198.796 million, up from $179.133 million as of December 31, 2024, reflecting an increase of approximately 11%[23] Expenses and Liabilities - Research and development expenses for Q1 2025 were $16,364,000, up from $12,236,000 in Q1 2024, indicating a rise of about 33.5%[21] - The company’s accumulated deficit increased to $535,947,000 as of March 31, 2025, compared to $509,601,000 as of December 31, 2024, reflecting a growth in the deficit of approximately 5.2%[20] - The contingent consideration liability related to the acquisition of Totient, Inc. was $12.750 million as of March 31, 2025, unchanged from December 31, 2024[41] - The company has financial commitments of $2.0 million, $4.6 million, $8.3 million, and $2.3 million for the years 2025 through 2028 under its agreement with Oracle Cloud Infrastructure[43] Shareholder Activity - The weighted-average common shares outstanding increased to 124,461,439 in Q1 2025 from 99,393,333 in Q1 2024, representing an increase of approximately 25.3%[21] - The company issued common shares, net of issuance costs, totaling $41.689 million during the three months ended March 31, 2025, compared to $80.827 million for the same period in 2024, indicating a decrease of approximately 48%[25] - The company issued 5,269,192 shares during the three months ended March 31, 2025, generating net proceeds of $21.7 million from its at-the-market offering program[45] - A strategic collaboration with AMD resulted in the sale of 5,714,285 shares for net proceeds of $20.0 million, aimed at optimizing AI drug creation technologies[46] Strategic Focus - The company continues to rely on its Integrated Drug Creation platform for future growth and partnerships, emphasizing the importance of regulatory approvals and market acceptance for its product candidates[11] - The company’s approach to drug creation leverages generative AI and synthetic biology, aiming to enhance the design of antibody therapeutics[27] - The company has collaborative arrangements with several partners, including PrecisionLife and Memorial Sloan Kettering Cancer Center, which involve joint research and development activities[33] Stock Options - As of March 31, 2025, total unrecognized stock-based compensation related to stock options was $28.0 million, expected to be recognized over a remaining weighted average period of 2.3 years[49] - The estimated grant-date fair value of stock options for the three months ended March 31, 2025, was based on a volatility of 90%-92% and a risk-free interest rate of 4.0%-4.4%[50] - The company had 21,758,054 stock options outstanding as of March 31, 2025, with an average exercise price of $3.39 per share[49]

Financial Performance - Revenue for Q1 2025 was $1.2 million, up from $0.9 million in Q1 2024, representing a 33.3% increase[7] - Net loss for Q1 2025 was $26.3 million, compared to a net loss of $22.0 million in Q1 2024, reflecting a 19.1% increase in losses[9] Expenses - Research and development expenses increased to $16.4 million in Q1 2025 from $12.2 million in Q1 2024, a rise of 34.4%[8] - Selling, general, and administrative expenses rose to $9.5 million in Q1 2025 compared to $8.7 million in Q1 2024, an increase of 9.2%[9] Cash and Investments - Cash, cash equivalents, and short-term investments as of March 31, 2025, were $134.0 million, up from $112.4 million as of December 31, 2024[10] - Cash and cash equivalents increased to $46,995,000 in March 2025, compared to $41,213,000 in December 2024, marking a rise of 14.0%[20] Assets and Liabilities - Total assets increased to $232,447,000 in March 2025 from $213,608,000 in December 2024, representing an increase of 8.6%[20] - Current assets rose to $155,978,000 in March 2025, up from $133,831,000 in December 2024, reflecting a growth of 16.5%[20] - Total liabilities decreased slightly to $33,651,000 in March 2025 from $34,475,000 in December 2024, a reduction of 2.4%[20] - Total current liabilities decreased to $27,281,000 in March 2025 from $28,656,000 in December 2024, a decrease of 4.8%[20] Stockholders' Equity - Stockholders' equity increased to $198,796,000 in March 2025, up from $179,133,000 in December 2024, indicating a growth of 11.0%[20] - Additional paid-in capital rose to $734,711,000 in March 2025, up from $688,726,000 in December 2024, an increase of 6.7%[20] Debt - Long-term debt decreased to $2,544,000 in March 2025 from $2,733,000 in December 2024, a decline of 6.9%[20] Clinical Trials and Partnerships - Initiated dosing of participants in the first-in-human study of ABS-101, with interim data expected in the second half of 2025[1] - ABS-201 demonstrated high subcutaneous bioavailability of over 90% in non-human primates, with potential for Q8W-Q12W dosing intervals in humans[3] - Anticipation of Phase 1 clinical trial initiation for ABS-201 in early 2026, with potential interim efficacy readout in the second half of 2026[4] - The company expects to sign one or more drug creation partnerships, including with a large pharmaceutical company, in 2025[12] Study Details - The primary endpoint of the ABS-101 study is safety and tolerability, with approximately 40 healthy adult participants expected to enroll[4] Accumulated Deficit - The accumulated deficit increased to $(535,947,000) in March 2025 from $(509,601,000) in December 2024, reflecting a worsening of 5.2%[20] Accounts Payable - Accounts payable rose to $4,947,000 in March 2025, compared to $3,529,000 in December 2024, an increase of 40.2%[20]